- ASSISTANT PROFESSOR Medicine, Endocrinology, Diabetes and Bone Disease
Kumar A, Magnuson A. Rictor/mTORC2 regulates FoxO1 to control cell proliferation (in preparation)..;.
Gu Y, Lindner J, Kumar A, Yuan W, Magnuson A. Rictor/mTORC2 is essential for maintaining a balance between β cell proliferation and cell size. Diabetes 2011; 60(3): 827-837.
Kumar A, Lawrence JC Jr., Jung DY, Ko HJ, Keller SR, Kim JK, Magnuson MA, Harris TE. Fat cell-specific ablation of Rictor in mice impairs insulin-regulated fat cell and whole body glucose and lipid metabolism. Diabetes 2010; 59(6): 1397-1406.
Kim HB, Kumar A, Wang L, Keller SR, Lawrence JC Jr., Finck BN, Harris TE. Lipin 1 represses NFATc4 transcriptional activity to inhibit adipocyte secretion of inflammatory factors. Molecular and Cellular Biology 2010; 30(12): 3126-3139.
Kumar A, Harris TE, Keller SR, Choi KM, Magnuson MA, Lawrence JC Jr.. Muscle-specific deletion of Rictor impairs insulin-stimulated glucose transport and enhances basal glycogen synthase activity. Molecular and Cellular Biology 2008; 28(1): 61-70.
Harris TE, Huffman TA, Chi A, Shabonawitz J, Hunt DF, Kumar A, Lawrence JC Jr.. Insulin controls subcellular localization and multisite phosphorylation of the Phosphatidic acid phosphatase, Lipin1. Journal of Biological Chemistry 2007; 282(1): 277-286.
Kumar A, Xiao YP, Laipis PJ, Fletcher BS, Frost SC. Glucose deprivation enhances targeting of GLUT1 to lipid rafts in 3T3-L1 adipocytes. American Journal Physiology Endocrinology Metabolism 2004; 286(4): E568-76.
Marita AR, Kumar A. Effect of vanadate on Glycogen synthesis in dexamethasone-treated 3T3 adipocytes: evidence for a novel insulin sensitizing action. Diabetes, Obesity and Metabolism 2001; 3: 271-278.
A. Kumar KL, Marita AR. Troglitazone prevents and reverses dexamethasone induced insulin resistance on glycogen synthesis in 3T3 adipocytes. British Journal of Pharmacology 2000; 130: 351-358.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Laxman did not report having any of the following types of financial relationships with industry during 2014 and/or 2015: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
Atran Berg Laboratory Building Floor 5 Room AB5-17
1428 Madison Avenue
New York, NY 10029